Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Rallybio Corp RLYB

Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:RLYB)

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Business Wire 2 days ago

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Business Wire 3 days ago

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Business Wire 4 days ago

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Business Wire 8 days ago

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Business Wire November 7, 2024

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Business Wire October 29, 2024

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

Business Wire September 30, 2024

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Business Wire September 23, 2024

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit

Business Wire September 10, 2024

Opinion & Analysis (NDAQ:RLYB)

No current opinion is available.

Bullboard Posts (NDAQ:RLYB)

Rallybio Corporation (NASDAQ:RLYB): A Promising Rare Disease

http://beyondspx.com/2024/07/31/rallybio-corporation-nasdaqrlyb-a-promising-rare-disease-biotech-with-multiple-clinical-stage-assets-2/
MikeTester - August 2, 2024

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeu

News; $RLYB Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday | BenzingaU...
whytestocks - April 11, 2024

Rare Disease-Focused Rallybio Inks Development Pact With Joh

Breaking News: $RLYB Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher...
whytestocks - April 11, 2024